<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542436</url>
  </required_header>
  <id_info>
    <org_study_id>ML29965</org_study_id>
    <nct_id>NCT02542436</nct_id>
  </id_info>
  <brief_title>Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population</brief_title>
  <official_title>An Observational Study to Investigate the Real World Effectiveness of Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in the UK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will focus on participants in the United Kingdom (UK) to collect local data on the
      effectiveness and safety of bevacizumab (Avastin) in the treatment of metastatic colorectal
      cancer in normal clinical use.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">September 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2015</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of metastatic colorectal cancer diagnosis to date of death up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>From date of metastatic colorectal cancer diagnosis to end of study up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of metastatic colorectal cancer diagnosis to end of study up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest</measure>
    <time_frame>From date of metastatic colorectal cancer diagnosis to end of study up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: bevacizumab</arm_group_label>
    <description>Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: no bevacizumab</arm_group_label>
    <description>Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention administered in this study</description>
    <arm_group_label>Cohort 1: bevacizumab</arm_group_label>
    <arm_group_label>Cohort 2: no bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with metastatic colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been diagnosed with metastatic colorectal cancer (mCRC)

          -  Have a Performance Status (PS) of 0-2, according to the Eastern Cooperative Oncology
             Group (ECOG) criteria at initiation of bevacizumab treatment

          -  Be chemotherapy-naive at diagnosis of mCRC or have relapsed more than 12 months after
             receiving adjuvant chemotherapy for early stage colorectal cancer

          -  Have received standard fluoropyrimidine-based chemotherapy for first-line treatment of
             mCRC with or without bevacizumab

          -  Have sufficient medical records available for assessment of eligibility at the
             Christie Hospital National Health Service (NHS) Trust, Manchester, United Kingdom

          -  For Cohort 1 (post CDF funding availability): patients between 2010-2013 who received
             bevacizumab with first-line chemotherapy

          -  For Cohort 2 (pre Cancer Drugs Fund [CDF] funding availability): patients propensity
             matched to cohort 1 between 2005-2008 who did not receive bevacizumab with first-line
             chemotherapy

        Exclusion Criteria:

          -  Subjects with metastatic colorectal cancer, who have received bevacizumab via a
             clinical trial

          -  Subjects with metastatic colorectal cancer, whose medical records are not complete
             enough to confirm eligibility for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

